SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Exploring Tau-C, Tau-A, and C1M as biomarkers for Parkinson's disease.

Front Neurol · 2025-04-30

DOI: 10.3389/fneur.2025.1566228PMID: 40371089

Open accessbrief-report; Journal ArticleOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

Tau has shown to be associated with neurodegenerative diseases. In this exploratory study, we investigated the utility of blood-based biomarkers measuring Tau-C, Tau-A, and C1M in Parkinson's disease (PD) to explore their potential as diagnostic biomarkers in two independent cohorts (TAU-C and TAU-A). We found them to discriminate between healthy donors and PD individuals (all p < 0.001), with Tau-C showing the best diagnostic discrepancy (AUROC = 0.97). Therefore, Tau-C, Tau-A, and C1M may be biomarkers for PD diagnosis.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.